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ABSTRACT 
In an effort to comprehensively characterize an antioxidant 
profile of 2-alkoxyphenylcarbamic acid-based compounds containing 
a 4´-(substituted phenyl)piperazin-1´-yl fragment, they were in 
vitro screened in the 2,2´-azino-bis(3-ethylbenzothiazoline-6-
-sulfonic acid) derived radical cation (ABTS•+) and ferric reducing 
antioxidant power (FRAP) assay using the UV/VIS 
spectrophotometry. The ABTS•+ scavenging (reducing) potential of 
1-[3-(2-methoxyphenylcarbamoyl)oxy-2-hydroxypropyl]-4-(4-
-fluorophenyl)piperazin-1-ium chloride was found to be the most 
promising and it was comparable to the efficiency of the carvedilol 
reference drug. Moreover, that 4´-fluoro group-containing 
compound was regarded as more active than the atenolol 
standard. When testing the molecules´ power to reduce the ferric 
2,4,6-tris (2-pyridyl)-s-triazine complex [Fe(III)(TPTZ)2]
3+, the 
most prospective was 1-[3-(2-ethoxyphenylcarbamoyl)oxy-2-
-hydroxypropyl]-4-(4-fluorophenyl)piperazin-1-ium chloride. On 
the other hand, its Fe3+ reducing power was lower compared 
to both standards carvedilol and atenolol. The study discussed 
structure–antioxidant properties relationships considering 
electronic, steric and lipophilic features. 
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INTRODUCTION 
Cardiovascular disease (CVD) is still the 
most common cause of death in Europe, 
causing almost twice as many deaths as cancer 
across the continent and places a substantial 
burden on the health care systems and 
economies of Europe. Mortality and morbidity 
from the CVD continue to have a major social 
and economic impact in Europe and significant 
inequalities are evident between countries. 
There have been major improvements in recent 
years on many measures of the CVD, however, 
these improvements have not been universal 
and substantial inequalities persist (Nichols et 
al., 2013; Townsend et al., 2015; Townsend et 
al., 2016). 
Notable evidence-based lifestyle inter-
ventions, as non-pharmacological approaches, 
leading to the changes in a diet, physical 
activity, and functional parameters can produce 
modest but clinically significant weight loss, 
reduce the prevalence of a type 2 diabetes mellitus 
and improve cardiovascular risk factors and 
mortality for the people, who are not 
overweight (Antala et al., 2008; Eguchi et al., 
2014; Gillet et al., 2012; Kyselovičová et al., 
2014; Loveman et al., 2011; Tibenská and 
Medeková, 2014). 
In the viewpoint of a pharmacological 
therapy of the CVD, the use of the β-adreno-
ceptor antagonists (β-AdrAs), which have shown 
notable cardioprotective and antioxidant 
properties, could be very beneficial. One of the 
best examples of such a drug has been 
lipophilic, a non-selective third-generation 
carvedilol (Book, 2007; Dandona et al., 2007). 
In addition, several metabolites of carvedilol 
have been considered extremely strong anti-
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oxidants, being 30- to 80-fold more efficient 
than carvedilol and up to 1000-fold more 
potent than vitamin E (Feuerstein et al., 1997; 
Kramer and Weglicki, 1996). 
Presently investigated 2-alkoxy substituted 
phenyl carbamic acid-based compounds 1–4 
have shown some common structural features, 
as carvedilol (Figure 1). Particularly, the 
molecules 1–4 have contained (i) a lipophilic (2-
alkoxy substituted) aromatic ring (the fragment 
A in Figure 1), (ii) a hydrophilic (carbamoyloxy) 
bridge (B) attached to (iii) a 2-hydroxypropane-
1,3-diyl connecting chain (C) and (iv) a basic 
centre of protonation (D). 
Following physicochemical properties of 
the mentioned compounds, carvedilol was 
considered slightly more basic with 
potentiometrically estimated dissociation 
constant (pKa) of 7.97 (Caron et al., 1999) than 
the substances 1–4, which pKas were found in 
the interval of 5.83 (the compound 3) to 6.73 
(1), as published by Malík et al. (2005; 2006). On 
the other hand, the most of the β-AdrAs 
(acebutolol, alprenolol, atenolol, and carazolol, 
for example) has shown similar values of the 
pKa of around 9.50 (Caron et al., 1999). The 
origin of thus discrepancy in the pKas between 
carvedilol and the other β--AdrAs was 
attributed to an inductive effect of a β-O-atom, 
which lowered the basicity of an amino group. 
In addition, the derivatives 1–4 were 
regarded as highly lipophilic compounds (Malík 
et al. 2005; Malík et al., 2006) with the log Pexp 
values in the range of 3.57 (3) to 3.90 (2), 
as listed (Table I). Their lipophilicity was 
comparable to those of carvedilol with 
log Pexp=3.40 estimated in the octan-1-
-ol/buffer partitioning system (Yue et al., 1992). 
Those backgrounds have motivated the 
current research to (i) investigate under the 
in vitro conditions, whether any of that 
prospective β-AdrAs 1–4 could be potential 
antioxidants in terms of their capability to 
scavenge the 2,2´-azinobis(3-ethylbenzotia-
zoline-6-sulfonic acid) derived radical cation 
(ABTS•+) and reduce the ferric 2,4,6-tris (2-
-pyridyl)-s-triazine complex [Fe(III) (TPTZ)2]3+ 
by using the UV/VIS spectrophotometry; 
(ii) reveal some structural, electronic and 
physicochemical features of those substances, 
which might appear to be essential for their 
antioxidant potential. 
 
 
 
Figure 1. Chemical structure of carvedilol and 
currently screened 1-[3-(2-alkoxyphenylcarbam- 
oyl)oxy-2-hydroxypropyl]-4-(4-fluoro-/3-tri- 
fluoromethylphenyl)piperazin-1-ium chlorides 
1–4 
 
MATERIALS AND METHODS 
The compounds under the study, reference 
drugs, reagents and solvents 
The currently in vitro screened 
compounds 1–4 (Figure 1), chemically 1-[3-(2-
-methoxyphenylcarbamoyl)oxy-2-hydroxyprop- 
yl]-4-(4-fluorophenyl)piperazin-1-ium chloride 
(1), 1-[3-(2-ethoxyphenylcarbamoyl)oxy-2-hydr- 
oxypropyl]-4-(4-fluorophenyl)piperazin-1-ium 
chloride (2), 1-{2-hydroxy-3-(2-methoxyphenyl- 
carbamoyl)oxy)propyl}-4-(3-trifluoromethyl-
phenyl)piperazin-1-ium chloride (3) and 1-{2-
-hydroxy-3-(2-ethoxyphenylcarbamoyl)oxy)- 
propyl}-4-(3-trifluoromethylphenyl)piperazine-
-1-ium chloride (4), were synthesized previously 
(Malík et al., 2004; Malík et al., 2006). Their 
experimentally observed pKa values, which were 
determined by a potentiometric titration, and 
the log Pexps estimated by a classical shake flask 
method (Table I) were already published in the 
research papers of Malík et al. (2005; 2006). 
Other compounds, which were used in 
performed in vitro experiments as the standard 
drugs, were purchased from Sigma-Aldrich 
(Germany) showing the purity of an analytical 
grade: Atenolol (ATN) and carvedilol (CRV), 
respectively, as the compounds, which have 
possessed antioxidant features (Book, 2007; 
Dandona et al., 2007; Gomes et al., 2006). 
Ivan Malík 
Volume 28 Issue 1 (2017) 3 
Furthermore, potassium persulfate 
(Sigma-Aldrich, Germany), 2,2´-azino-bis(3-
-ethylbenzothiazoline-6-sulfonic acid) (ABTS; 
Sigma-Aldrich, Germany) and ethanol 
(CentralChem, Slovak Republic) were used to 
measure the antioxidant capability of the 
molecules 1–4 and the reference drugs by the 
2,2´-azino-bis(3-ethylbenzothiazoline-6-sulfonic 
acid) derived radical cation (ABTS•+) method. 
The ethanol solvent was dried before use. 
The following chemicals were used to 
estimate the antioxidant potency by the ferric 
reducing antioxidant power (FRAP) assay: 
Ferric chloride hexahydrate, sodium acetate 
trihydrate, glacial acetic acid, concentrated 
hydrochloric acid (all the reagents and solvents 
were purchased from CentralChem, Slovak 
Republic) and 2,4,6-tris (2-pyridyl)-s-triazine 
(TPTZ; Sigma-Aldrich, Germany). 
 
The in vitro investigation of the 
antioxidant potential by the 2,2´-
-azinobis(3-ethylbenzotiazoline-6-sulfonic 
acid) derived radical cation (ABTS•+) 
assay 
The ABTS•+ decolourisation assay was 
carried out according to the method developed 
earlier by Rice-Evans et al. (1996) and Re et al. 
(1999) with some modifications of Iqbal et al. 
(2014). 
In brief, a stock solution of 2,2'-azino- 
bis(3-ethylbenzothiazoline-6-sulfonic acid) 
diammonium salt radical cation (ABTS•+) was 
prepared by dissolving 0.038g of ABTS in 
10mL of distilled water, then 0.270g of 
potassium persulfate was added in the solution. 
The ABTS, a colorless parent 
compound, was used because of its high 
chemical stability, high water solubility and its 
UV/VIS absorption spectrum with a maximum 
at λmax=340nm (Cano et al., 1998). In the assay, 
the potassium persulfate reagent has shown the 
ability to oxidize ABTS to the radical cation 
ABTS•+, a long-living species with high 
extinction coefficients at 416, 650, and 734nm 
(Campos and Lissi, 1997). 
Because ABTS and potassium persulfate 
reacted stoichiometrically at a ratio of 1:0.5, 
that would result in an incomplete oxidation of 
the ABTS. The oxidation of ABTS commenced 
immediately, but the absorbance was not 
maximal and stable until more than 6h had 
elapsed (Re et al., 1999). 
Following given, the stock solution of 
ABTS•+ was kept in dark for 24h at room 
temperature in order to generate deep colored 
radical containing solution. After that period, 
the volume of 1.1mL of the concentrated 
radical was transferred into a 50-mL volumetric 
flask and made up with an anhydrous ethanol. 
It was proven that the radical cation ABTS•+, a 
blue-green chromogen (chromophore), was 
stable for more than 48h when stored in the 
dark at room temperature (Re et al., 1999) from 
pH=3.0 to 6.5, however, unstable above 35°C 
(Cano et al., 1998). 
Before each analysis session, the ABTS•+ 
solution was diluted with an anhydrous ethanol 
to an absorbance of 1.00±0.02 at 734nm. 
Although Re et al. (1999) or Katalinic et al. 
(2005) recommended ABTS•+ with the 
absorbance of approximately 0.70±0.02, the 
authors of a current article found that the using 
a higher concentration allowed the testing of 
a more extended range of antioxidant 
concentrations. 
After the addition of 2.0mL working 
ethanolic ABTS•+ solution to 100μL of each 
compound (c=1×10-3mol/L), the particular 
mixture was stirred for 30 seconds and the 
absorbance was measured after additional (i) 
4min and 30s (overall time was 5 minutes) and 
(ii) 59min and 30s (overall time was 1 hour) as 
well at λ=734nm using the UV/VIS 
spectrophotometer HP 8453 (Hewlett Packard, 
USA). 
The extent of decolourisation as the 
percentage inhibition of ABTS•+ was determined 
relative to the measured absorbance of the 
control. When the antioxidant was added and 
mixed, the drop in the absorbance (Acontrol–
Asample) was measured after given reaction 
periods. 
The percentages of the ABTS•+ 
scavenging (reduction) were calculated after 
5min and 1h, respectively, according to the 
equation given below: 
 
%ABTS•+= 
100×(Acontrol–Asample) 
Acontrol 
 
where  %ABTS•+  was  the  percentage of  the  
Antioxidant Properties of 2-Alkoxyphenylcarbamic Acid 
Volume 28 Issue 1 (2017) 4 
ABTS•+ scavenging, Asample and Acontrol were the 
absorbances at λ=734nm before (Acontrol) and 
after 5min (and 1h) adding samples to the 
ABTS•+ working solution, respectively. 
Those %ABTS•+ values were presented 
as means ± standard deviation (SD) of at least 
triplicate experiments (Table II). 
 
The in vitro investigation of the 
antioxidant potential by the ferric ion 
reducing antioxidant power (FRAP) 
assay 
The FRAP assay took an advantage of 
an electron transfer reaction (Benzie and Strain, 
1996), in which a ferric salt [Fe(III)(TPTZ)2]Cl3 
was used as an oxidant. That method depended 
upon the reduction of a colorless ferric 2,4,6-
-tris (2-pyridyl)-s-triazine complex [Fe(III)(TPT 
Z)2]3+ to the blue-coloured ferrous 2,4,6-tris (2-
-pyridyl)-s-triazine one [Fe(II)(TPTZ)2]2+. 
In other words, the antioxidant potentials 
of the compounds were estimated as their 
power to reduce the [Fe(III)(TPTZ)2]3+ complex 
to the [Fe(II)(TPTZ)2]2+ one. 
The difference between the ABTS•+ and 
FRAP assay was that the first one occurred at 
a neutral pH (Re et al., 1999) whereas the FRAP 
assay needed acidic conditions, it means the 
pH=3.6 (Benzie and Strain, 1996). 
A 300mmol/L acetate buffer of pH=3.6 
(3.1g of sodium acetate trihydrate and 16mL of 
a glacial acetic acid made up to 1000mL with 
distilled water), 10mmol/L 2,4,6-tris (2-pyridyl)-
-s-triazine (TPTZ; 3.1mg/mL in 40mmol/L 
hydrochloric acid) and 20mmol/L ferric 
chloride hexahydrate (5.4mg/mL in distilled 
water) were mixed together in a volume ratio of 
10:1:1 (25mL of the acetate buffer, 2.5mL of 
a TPTZ solution and 2.5mL of a ferric chloride 
hexahydrate solution), respectively, as required 
to give the working FRAP reagent. That FRAP 
working solution must be always freshly 
prepared (Benzie and Strain, 1996; Then et al., 
2003). 
The temperature of the FRAP working 
reagent was raised to 37°C before use and 
allowed to react (3mL) with the prepared 
solution of each evaluated compound (100μL, 
c=1×10-3mol/L). 
The absorbance value was recorded after 
5min as well as 1h with the UV/VIS 
spectrophotometer HP 8453 (Hewlett Packard, 
USA). The formed [Fe(II)(TPTZ)2]2+ complex 
has shown an intensive blue color, which was 
monitored at λ=593nm. Increased absorbance 
at that wavelength indicated a stronger reducing 
power. 
The antioxidant efficiency of the 
compounds 1–4 after 5min and 1h, respectively, 
was calculated as the ascorbic acid equivalent 
(AAE; the analogical amount of ascorbic acid 
expressed in the mg/mL units) according to the 
equation bellow: 
 
AAE= 
A 
0.134 
 
where AAE meant ascorbic acid equivalent and 
the A parameter was the absorbance of the 
sample. 
Those AAE data were presented as 
means ± standard deviation (SD) of at least 
triplicate experiments (Table II). 
 
RESULTS AND DISCUSSION 
Following the chemical structure of 
currently in vitro screened compounds 1–4, their 
capability to scavenge a large nitrogen-centered 
and sterically-hindered blue-green radical cation 
ABTS•+ and a colourless [Fe(III)(TPTZ)2]3+ 
complex could be dependent on: (i) electronic, 
steric and lipohydrophilic properties of the R2 
substituent attached to the salt-forming moiety 
and (ii) a length of the R1 group of a lipophilic 
part (Table I). Possible impacts of given aspects 
were discussed in next sections of the paper. 
 
Table I. Experimentally observed values of the 
dissociation constants (pKa) by the 
potentiometric titration and the partition 
coefficients (log Pexp) of the compounds 1–4 
determined in the octan-1-ol/phosphate buffer 
(pH=7.4) 
 
Entry R1 R2 pKa log Pexp 
1 2-OCH3 4´-F 6.73 3.61 
2 2-OC2H5 4´-F 6.58 3.90 
3 2-OCH3 3´-CF3 5.83 3.57 
4 2-OC2H5 3´-CF3 6.00 3.60 
 
Electronic properties of substituents 
might be described by the Hammett substituent 
constant σ; a more positive value of σ means a 
stronger electron-withdrawing influence of the 
substituent (Kubinyi, 1993). The σ output for 
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the 4´-F substituent (σ4´-F) was 0.06, the σ value 
related to the 3´-CF3 moiety (σ3´-CF3) was set to 
0.43 and that parameter for a hydrogen atom 
(σH) was 0.00. 
The electronic features of all the in vitro 
studied 2-alkoxyphenylcarbamates/N-
arylpiperazines 1–4 could be also characterized 
by the values of their dissociation constants pKa 
(Table I). It was found that the presence of the 
4´-F substituent provided higher values of the 
compounds’ pKa, which were observed in the 
range of 6.58 (2) to 6.73 (1). The introduction 
of a 3´-CF3 moiety led to lower pKas, namely 
the pKa=5.83 was estimated for the substance 3 
and the pKa=6.00 was found for the derivative 
4 (Malík et al., 2005; Malík et al., 2006). 
Furthermore, the values of representative 
steric descriptors L and Bi–Biv (Kubinyi, 1993) 
proved that the 3´-CF3 group was sterically 
almost twice as bulky than the 4´-F one. 
The presence of a 4´-F substituent 
(compounds 1 and 2) provided only a very 
slight advantage for those screened derivatives 
in their capability to scavenge (reduce) the 
radical cation ABTS•+ after 5min as well as 1h 
compared to the potential of the 3´-CF3 
substituted compounds (3 and 4; Table II). 
 
Table II. The in vitro capability of the 
compounds 1–4 and the reference drugs 
atenolol (ATN) and carvedilol (CRV) to 
scavenge (reduce) the radical cation ABTS•+ 
(%ABTS•+) and reduce the [Fe(III)(TPTZ)2]3+ 
complex (the ascorbic acid equivalent; AAE) 
 
Entry 
%ABTS•+ (%) AAE (mg/mL) 
5min 1h 5min 1h 
1 
16.82 
±0.62 
35.22 
±1.03 
1.28 
±0.02 
2.62 
±0.05 
2 
6.67 
±0.10 
21.98 
±0.44 
1.50 
±0.02 
3.02 
±0.07 
3 
14.49 
±0.21 
32.90 
±0.72 
1.26 
±0.06 
2.32 
±0.03 
4 
8.78 
±0.25 
19.46 
±0.33 
1.51 
±0.04 
2.26 
±0.04 
ATN 
9.89 
±0.12 
32.66 
±1.05 
1.82 
±0.12 
3.88 
±0.05 
CRV 
18.36 
±0.72 
45.84 
±1.35 
2.03 
±0.14 
4.08 
±0.09 
 
The most promising potential to 
scavenge the radical cation ABTS•+ after 5min 
was found for both 1-[3-(2-methoxyphenyl- 
carbamoyl)oxy-2-hydroxypropyl]-4-(4-fluoro-
phenyl)piperazin-1-ium chloride (1) with the 
%ABTS•+=16.82±0.62% and 1-{2-hydroxy-3-
-(2-methoxyphenylcarbamoyl)oxy)propyl}-4-(3-
trifluoromethylphenyl)piperazin-1-ium chloride 
(3) with the %ABTS•+=14.49±0.21%. Their 
efficiency was comparable to the antioxidant 
action of the carvedilol (CRV) reference drug, 
which has shown the %ABTS•+=18.36±0.72%. 
Both derivatives 1 and 3 were considered more 
prospective than the atenolol (ATN) standard 
drug with %ABTS•+=9.89±0.12% (Table II). 
The measurements after 1h led to higher 
%ABTS•+ data for all the investigated substances 
1–4, the ABTS•+ scavenging process was the 
most notable under the influence of a molecule 
1 with the %ABTS•+=35.22±1.03% and 3, 
which has shown the %ABTS•+=32.66±1.05%. 
Those derivatives were more potent than the 
ATN standard (Table II). On the other hand, 
the CRV reference substance was regarded as 
the most effective within an entire set of 
investigated compounds showing the 
%ABTS•+=45.84±1.35% (Table II). 
Indeed, it was found practically no 
difference in the potential of the compounds 1 
and 3 to scavenge (reduce) the radical cation 
ABTS•+ after 5min as well as 1h, regardless of 
very slight/strong electron-withdrawing 
properties or steric features of the R2 
substituent. 
The 4´-F substitution on the aromatic 
system of the molecules 1 and 2 rendered the 
remaining aromatic hydrogen substituents 
slightly more acidic, so the capacity of that 
compounds to act as hydrogen bridge donors 
has been moderately enhanced. On the other 
hand, not only one free electron pair of that 
fluorine atom could act as the hydrogen bridge 
acceptor. The aromatic π electron system of the 
4´-(substituted phenyl)piperazin-1´-yl fragment 
could serve as the electron donor site due to 
only a slight decrease in an electron density of 
a phenyl ring. 
An insight into the chemical structure of 
the compounds 3 and 4 indicated that the 
ability of fluorines of the 3´-CF3 group to act as 
hydrogen bridge acceptors has been enhanced 
due to a strong electron-withdrawing effect 
and, furthermore, the acidity of aromatic 
Antioxidant Properties of 2-Alkoxyphenylcarbamic Acid 
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hydrogens let them considered potential 
hydrogen bond donors. 
Mistry et al. (2016, 2017) noticed that the 
antioxidant activity of the substituted N-
-arylpiperazine-based berberine compounds 
were considerably dependent on the 
substitution of the aromatic system. Different 
electron--withdrawing functional groups such 
as chloro, fluoro, nitro as well as the electron-
donating one (methyl) were attached to the 4-
-(substituted phenyl)piperazin-1-yl moiety. The 
compounds containing 4-(3-chloro-/4-chloro-
/2-fluoro- or 4-fluorophenyl)piperazin-1-yl were 
considered the most promising in terms of the 
ability to scavenge the ABTS•+. On the other 
hand, the molecules, in which structure was 
incorporated 4-(4-methyl-/2-nitro-/4-nitro- or 
4-trifluoromethylphenyl)piperazin-1-yl, were less 
efficient. 
It would be preliminary stated that the 
most prospective derivative 1 was the most 
basic with the pKa=6.73. However, that output 
was one magnitude down compared to those of 
the CRV standard drug (the pKa=7.97; Caron et 
al., 1999). 
Furthermore, the increase in lipophilicity 
of the inspected molecules due to the 
elongation of a 2-alkoxy side chain (the 
compound 1 versus 2 and 3 versus 4, respectively) 
led to lower %ABTS•+s (Table II). The most 
efficient substances 1 (log Pexp=3.61) and 3 
(log Pexp=3.57) have shown the log Pexps, which 
were very close to those of CRV (log Pexp=3.40; 
Yue et al., 1992). 
The FRAP assay was employed to 
inspect the Fe3+ ion reducing capabilities of the 
title compounds 1–4. The measurements of the 
absorbance values after 5min revealed that the 
derivatives, which reduced the metal ion 
complexes to their lower oxidation state in that 
assay most markedly, were 1-[3-(2-
-ethoxyphenylcarbamoyl)oxy-2-hydroxypropyl]-
-4-(4-fluorophenyl)piperazin-1-ium chloride (2; 
AAE=1.50±0.02mg/mL) and 1-{2-hydroxy-3-
-(2-ethoxyphenylcarbamoyl)oxy)propyl}-4-(3-
-trifluoromethylphenyl)piperazin-1-ium chlo- 
ride (4; AAE=1.51±0.04), as listed in Table II. 
It could be stated that in the FRAP 
assay, an opposite trend of the results appeared 
when compared to the data, which were 
observed by the ABTS•+ method. It was found 
that the increase in lipophilicity of a whole 
molecule was the most essential for its ability to 
reduce the [Fe(III)(TPTZ)2]3+ complex. 
In addition, the dependence between the 
pKas and the AAE values would not be correct 
to clearly interpret due to a relatively limited set 
of inspected compounds. 
As mentioned, both compounds 2 and 4 
have shown a high lipophilicity, the 
log Pexp=3.90 was estimated for the substance 
2, the log Pexp=3.60 was related to the 
derivative 4 (Malík et al. 2005; Malík et al., 
2006). On the other hand, the ATN and CRV 
reference drugs were slightly more prospective 
with the AAE=1.82±0.12mg/mL (ATN) and 
2.03±0.14mg/mL (CRV; Table II). 
The potential of the compounds 1–4 to 
reduce the [Fe(III)(TPTZ)2]3+ complex after 1h 
within the process of the FRAP assay was 
slightly changed. It was confirmed that the 
most lipophilic substance 2 was the most 
effective, as the AAE=3.02±0.07mg/mL has 
shown. In general, the 4´-F substituted 
compounds (1 and 2) were more promising 
compared to those with a 3´-CF3 group (3 and 
4). From an entire investigated set of the 
substances, the CRV standard drug was the 
most efficient, that molecule has shown the 
AAE=4.08±0.09mg/mL (Table II). 
Predominant features of a fluorine-
-containing substituents have been their strong 
electronegativity and their extremely low 
polarizability. Thus, depending on the interaction 
partner, steric interactions can be dominated 
either by the attractive complementary 
distribution of partial charges, e.g. hydrogen 
bonding to a fluorine or by the strong 
electrostatic repulsion of tightly bounded lone 
electron pairs in steric fluorine–fluorine 
interactions (Kirsch, 2004). In regard to the 
steric properties, a simplistic comparison 
between the „size“ of hydrogen, fluoro and 
fluorocarbon substituents must be made with 
care. 
Indeed, for a clarification of the steric 
impacts of the fluorine-containing substituents 
on the scavenging the radical cation           
ABTS•+ and reduction of the [Fe(III)(TPTZ)2]3+ 
complex, another in vitro experiments will be 
presented in further research papers regarding 
structurally  very  similar  compounds. The     only 
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structural difference   between   investigated   
sets  of  the molecules will be in the salt-
forming moiety, which will be formed by the 
4´-(2´-fluorophen-yl)piperazin-1´-yl fragment. 
 
CONCLUSION 
Part of beneficial cardiovascular effects 
shown by β-adrenoceptor antagonists has 
already been associated with the antioxidant 
properties that some of them seem to possess. 
The series of such perspective molecules, the 2-
-alkoxyphenylcarbamic acid esters, which 
contained 4´-(4´-fluoro-/3´-trifluoromethyl- 
phenyl)piperazin-1´-yl moiety, has been 
evaluated for its capability to in vitro scavenge 
the radical cation ABTS•+ and reduce the 
[Fe(III)(TPTZ)2]3+ complex. 
The major novel findings of the current 
study have been that the ability of those 
screened compounds to scavenge the ABTS•+ 
was increased by the presence of a 4´-F 
substituent, which has probably shown 
convenient electronic, steric and 
lipohydrophilic properties. Moreover, the 
highest effectiveness of the tested molecules 
was related to a certain level of their 
lipophilicity, which could be expressed by the 
log Pexp of approximately 3.60. The further 
increase in lipophilicity led to the decrease in a 
potency. 
On the other hand, the 
[Fe(III)(TPTZ)2]3+ complex reduction was 
most efficient by the most lipophilic substance 
(log Pexp=3.90) within the investigated set of 2-
-alkoxyphenylcarbamic acid-based compounds. 
Given molecule contained sterically less bulky 
substituent attached to a 4´-(substituted phenyl) 
piperazin-1´-yl moiety with only a slight 
electron-withdrawing properties. Furthermore, 
the linearity of the salt-forming fragment was 
regarded as the favorable structural feature. 
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